title: [GnRH agonist/hMG stimulation in gamete intrafallopian transfer (GIFT)].
abstract: During a period of 17 months 61 couples without pathological tubal factors were treated by follicular puncture and gamete intra-Fallopian transfer (GIFT) at the department of Obstretrics and Gynaecology, University of Hamburg. The combination GnRH-antagonist (GnRH-A)/hMG was administered in 69 stimulation cycles. Two different GnRH-A application forms were used (daily intranasal spray/monthly depot injection). In all cases mature oocytes were collected after ovulation induction, and gamete transfer was performed. None of the cycles had to be cancelled. Twenty-two clinical pregnancies were achieved (32% by stimulation cycle). The highest pregnancy rate was observed in the group of cervical infertility (58%), lowest rate in cases of pathological male factors (15%). In addition, pregnancy rate correlated with the number and maturity of transfered oocytes. The combined GnRH-A/hMG stimulation therapy allows for a prolonged active follicular development without the occurrence of endogenous, premature luteinization. Besides a more flexible and effective strategy of ovarian stimulation, the number of follicles/oocytes was L, increased which provided a better condition for GIFT.
authors.affiliation: Abteilung für klin. u. exp. Endokrinologie, Universitäts-Frauenklinik Hamburg-Eppendorf.
authors.forename: C
authors.initials: C
authors.lastname: Lindner
authors.forename: W
authors.initials: W
authors.lastname: Braendle
authors.forename: V
authors.initials: V
authors.lastname: Lichtenberg
authors.forename: L
authors.initials: L
authors.lastname: Bispink
authors.forename: G
authors.initials: G
authors.lastname: Bettendorf
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D002064:Buserelin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D015181:Gamete Intrafallopian Transfer / Q000379:methods*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000628:therapy*; D007273:Injections, Intramuscular; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D011247:Pregnancy; D011256:Pregnancy Outcome; D017329:Triptorelin Pamoate
chemical_list: D003692:Delayed-Action Preparations; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D002064:Buserelin
vernacular_title: GnRH-Agonist/hMG-Stimulation für den intratubaren Gametentransfer (GIFT).